RBPJ Inhibitor-1 (RIN1), the first RBPJ inhibitor, blocks the functional interaction of RBPJ with SHARP. RBPJ Inhibitor-1 (RIN1) inhibits NOTCH-dependent tumor cell proliferation[1].

RIN1 inhibits the proliferation of hematologic cancer cell lines and promoted skeletal muscle diferentiation from C2C12 myoblasts[1].RIN1 (0.6 μM, corresponding to 3 × IC50) decreases the number of MHC+ cells and increased the number of nuclei per cell, indicating that it induces the formation of multinucleated myofbers[1]. Cell Viability Assay[1]Cell Line: AD-293 cells were transfected with RBPJ-VP16myc.

RBPJ Inhibitor-1

DMSO:250 mg/mL (803.06 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years